Viking Therapeutics VKTX Return on equity
Return on equity at other companies
Other financials
Where this comes from
Calculated from Viking Therapeutics’s reported figures.
Based on trailing twelve months.
The official record: Viking Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Viking Therapeutics's return on equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Viking Therapeutics's return on equity?
- Viking Therapeutics (VKTX) reported return on equity of -70% in Q1 2026.
- How has Viking Therapeutics's return on equity changed year-over-year?
- Viking Therapeutics's return on equity decreased by 386.3% year-over-year, from -14.4% to -70%.
- What is the long-term trend for Viking Therapeutics's return on equity?
- Over 5 years (2020 to 2025), Viking Therapeutics's return on equity has grown at a 25.6% compound annual growth rate (CAGR), from -15.1% to -47.3%.
- What does return on equity mean?
- Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.